Literature DB >> 20031718

Noncardiac surgery and bleeding after percutaneous coronary intervention.

Andrew C Y To1, Guy Armstrong, Irene Zeng, Mark W I Webster.   

Abstract

BACKGROUND: The decision on whether to implant a drug-eluting or bare-metal stent during percutaneous coronary intervention (PCI) depends in part on the perceived likelihood of the patient developing late stent thrombosis. Noncardiac surgery and bleeding are associated with discontinuation of dual antiplatelet therapy and with increased stent thrombosis. We assessed the incidence of and predictors for subsequent noncardiac surgery and bleeding episodes in patients who had undergone PCI. METHODS AND
RESULTS: Hospital discharge coding data were used to identify all adult patients undergoing public hospital PCI in New Zealand from 1996 to 2001. Hospital admissions during the ensuing 5 years were analyzed for noncardiac surgery and bleeding episodes. Eleven thousand one hundred fifty-one patients (age, 62+/-11 years; 30% women) underwent PCI, mainly for an acute coronary syndrome (73%). During the 5-year follow-up, 26% of the population underwent at least 1 noncardiac surgical procedure (23% orthopedic, 20% abdominal, 12% urologic, 10% vascular, 35% others) and 8.6% had at least 1 bleeding episode either requiring or occurring during hospitalization. Of those, half were gastrointestinal, and one quarter of bleeding events required blood transfusion. The main clinical predictors of noncardiac surgery were advanced age, previous noncardiac surgery, osteoarthritis, and peripheral vascular disease. A previous bleeding admission and age were the strongest predictors of subsequent bleeding.
CONCLUSIONS: Noncardiac surgery is required frequently after PCI, whereas bleeding is less common. Before implanting a drug-eluting or bare-metal stent, individual patient risk stratification by the interventional cardiologist should include assessment of whether there is an increased likelihood of needing noncardiac surgery or developing bleeding.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20031718     DOI: 10.1161/CIRCINTERVENTIONS.108.830158

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  11 in total

Review 1.  [Antiplatelet therapy after coronary stenting and its importance in total joint arthroplasty].

Authors:  N Harrasser; T Harnoss; F Brettner; F Liska; M Pauschinger
Journal:  Orthopade       Date:  2012-06       Impact factor: 1.087

Review 2.  Management of antiplatelet therapy inpatients at risk for coronary StentThrombosis undergoing non-cardiac surgery.

Authors:  Zuzana Motovska
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

Review 3.  Bridge with intravenous antiplatelet therapy during temporary withdrawal of oral agents for surgical procedures: a systematic review.

Authors:  Nuccia Morici; Lorenzo Moja; Valentina Rosato; Alice Sacco; Antonio Mafrici; Silvio Klugmann; Maurizio D'Urbano; Carlo La Vecchia; Stefano De Servi; Stefano Savonitto
Journal:  Intern Emerg Med       Date:  2014-01-14       Impact factor: 3.397

4.  Incidence, nature, and temporal trends of adverse events associated with noncardiac procedures among veterans with drug-eluting coronary artery stents.

Authors:  Charles Salters; Bruce Bradley; Richard J Charnigo; Zaman Shah; John Meehan; Ahmed Abdel-Latif; Khaled M Ziada
Journal:  Catheter Cardiovasc Interv       Date:  2015-05-06       Impact factor: 2.692

Review 5.  Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence.

Authors:  Jacek Budzyński; Marek Koziński; Maria Kłopocka; Julia Maria Kubica; Jacek Kubica
Journal:  Clin Res Cardiol       Date:  2014-05-10       Impact factor: 5.460

6.  Coronary artery disease: to cath or not to cath? When and how best to cath: those are the remaining questions.

Authors:  Roberta Rossini; Giuseppe Musumeci; Eliano Pio Navarese; Giuseppe Tarantini
Journal:  Am J Cardiovasc Dis       Date:  2013-02-17

7.  The Influence of Antiplatelet Drug Medication on Spine Surgery.

Authors:  Won Shik Shin; Dong Ki Ahn; Jung Soo Lee; In Sun Yoo; Ho Young Lee
Journal:  Clin Orthop Surg       Date:  2018-08-22

8.  Early surgery after coronary revascularization: a fine line between bleeding and thrombosis.

Authors:  C De Biase; E Capuano; S De Luca; C D'Anna; R Luciano; F Piscione; B Trimarco; G Galasso
Journal:  Transl Med UniSa       Date:  2014-12-19

9.  Dual antiplatelet therapy can be discontinued at three months after implantation of zotarolimus-eluting stent in patients with coronary artery disease.

Authors:  Tadashi Wada; Makoto Nakahama; Hironobu Toda; Atsuyuki Watanabe; Katsushi Hashimoto; Ritsuko Terasaka; Kazufumi Nakamura; Nobuyuki Yamada; Hiroshi Ito
Journal:  ISRN Cardiol       Date:  2013-04-04

10.  Prospective and systematic analysis of unexpected requests for non-cardiac surgery or other invasive procedures during the first year after drug-eluting stent implantation.

Authors:  Byeong-Keuk Kim; Jung-Han Yoon; Dong-Ho Shin; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Seung-Hwan Lee; Gary S Mintz; Yangsoo Jang; Myeong-Ki Hong
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.